Efficacy and Safety of TNX-102 SL* (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: **Results from the Randomized, Placebo-Controlled RELIEF Trial**



been approved for any indication

*TNX-102 SL is an investigational drug and has not

Seth Lederman, MD,¹ Lesley M. Arnold, MD,² Ben Vaughn, MS,³ Mary Kelley, MPH,¹ Gregory M. Sullivan, MD¹ ¹Tonix Pharmaceuticals, Inc., Chatham, NJ ²University of Cincinnati College of Medicine, Cincinnati, OH ³Rho, Inc, Chapel Hill, NC


INTRODUCTION

Fibromyalgia (FM) is characterized by chronic widespread pain, fatigue, and nonrestorative sleep that is linked to nociplastic pain (central sensitization). FM afflicts an estimated 6-12 million adults in the U.S., the majority of whom are women. Physicians and patients report common dissatisfaction with currently marketed products. TNX-102 SL ("TNX") is a patented sublingual tablet formulation of cyclobenzaprine HCl which provides rapid transmucosal absorption and reduced production of an active metabolite due to bypass of first-pass hepatic metabolism. TNX is a multifunctional agent with potent binding and antagonist activities at the 5-HT₂₄-serotonergic, α_1 -adrenergic, H₁-histaminergic, and M₁-muscarinic receptors. TNX is believed to work in FM by targeting improvement in sleep quality, which, in turn, reverses nociplastic pain. Previous Phase 2 and 3 trials of TNX at 2.8 mg showed signals for broad efficacy, including robust effects in sleep and other FM symptoms, but narrowly missed significance on the primary outcome of daily diary pain reduction. Accordingly, this Phase 3 trial ('RELIEF') evaluated efficacy and safety of TNX for FM at 5.6 mg.

METHODS

Phase 3 'RELIEF' was a double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of TNX. Intent-to-treat sample was made up of 503 patients meeting 2016 FM diagnostic criteria who were enrolled in the 14-week trial at 39 U.S. sites. Patients received TNX 2.8 mg or placebo for 2 weeks followed by TNX 5.6 mg or placebo for 12 weeks. Primary outcome measure was change from baseline in weekly average of daily diary pain scores (0-10 NRS) at Week 14. The 1st key secondary endpoint was proportion of responders who were "much improved" or "very much improved") on Patient Global Impression of Change (PGIC). Remaining key secondaries were: Fibromyalgia Impact Questionnaire-Revised (FIQ-R) symptom domain; FIQ-R function domain; Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance; PROMIS Fatigue; and daily diary NRS of sleep quality. Data were analyzed by mixed model repeated measures (MMRM) with multiple imputation for missing data or by logistic regression for PGIC. To adjust for multiplicity and control for overall type I error, a fixed sequence procedure was applied to the primary

Figure 2: Mean Change from Baseline in Weekly Averages of Daily NRS Pain Scores



The 1st key secondary endpoint, the PGIC responder analysis trended for a greater proportion of responders (rating of "very much improved" or "much improved" at Week 14) to TNX-102 SL (37.5%) compared with placebo (29.4%), but the result was not statistically significant (p=0.058) (Table 2). Due to the hierarchical statistical testing order, analyses of remaining endpoints are considered descriptive and are reported with nominal p-values. **Effects on Symptoms and Functioning as Measured by FIQ-R**




Table 2: Summary of Key Secondary Endpoints


Outcome Measure at Week 14	TNX-102 SL (N=248)	Placebo (N=255)	P-value
Non-Specific	%	%	
PGIC Responders	sponders 37.5%		0.058
Fibromyalgia Syndrome-Related	LS Mean [SE]	LS Mean [SE]	
FIQ-R Symptom Domain	-18.4 [1.21]	-14.0 [1.21]	0.007#
FIQ-R Function Domain	-13.6 [1.26]	-9.3 [1.26]	0.009#
PROMIS Sleep Disturbance	-9.5 [0.64]	-6.5 [0.61]	<0.001#
PROMIS Fatigue	-8.0 [0.58]	-6.2 [0.59]	0.018#
Daily Sleep Quality Diary, NRS	-2.0 [0.12]	-1.5 [0.12]	<0.001#

The syndromal activity of TNX was studied by the FIQ-R. TNX showed improvement over placebo in both the Symptom domain (LS mean difference [SE] = -4.3 [1.60] units; p=0.007) (Figure 4) and Function domain (-4.4 [1.69] units; p=0.009) (Figure 5).

Effects on Sleep and Fatigue as Measured by PROMIS

For the PROMIS Sleep Disturbance instrument, TNX substantially improved over placebo on T-scores (LS mean difference: -2.9 [0.82] units; p<0.001) (Figure 6). Additionally, TNX showed improvement over placebo on the PROMIS Fatigue instrument T-scores (-1.8 [0.76] units; p=0.018) (Figure 7).


Figure 3: Continuous Responder Analysis Graph



nominally significant

Figure 8: Mean Change from Baseline in Weekly Averages of Daily NRS Sleep Quality Scores

For the daily diary sleep quality ratings, TNX-102 SL (-2.0 [0.12] units) compared to placebo (-1.5 [0.12] units) was nominally significant (LS mean difference: -0.6 [0.17] units; p<0.001).



TNX-102 SL was similarly well tolerated as in Phase 2 BESTFIT and Phase 3 AFFIRM studies which both studied TNX at a lower dose of 2.8 mg daily. There were no new safety signals observed in the RELIEF study at the 5.6 mg daily dose. As expected, based on prior TNX-102 SL studies, administration site reactions are the most commonly reported adverse events and were higher in the TNX-102 SL treatment group, including rates of oral or tongue numbness or tingling, bitter or unpleasant aftertaste, and tongue pain (Table 3). The only systemic treatment-emergent adverse events that occurred at a rate of 3.0% or greater in the TNX arm were sedation, fatigue, and dry mouth, which are consistent with known side effects of marketed oral cyclobenzaprine. Adverse events resulted in premature study discontinuation in 8.9% of those who received TNX compared with 3.9% of placebo recipients. Among participants randomized to the TNX and placebo arms, 82.3% and 83.5%, respectively, completed the 14-week dosing period.


•	Investigator decision (N=1)
•	Withdrawal of consent by patient
	(N=11)
•	Lost to follow-up (N=9)
•	COVID-19 crisis (N=3)
•	Non-compliance (N=1)
•	Other (N=0)
	Completed (N=213)

As seen in **Table 1**, no clinically important differences in baseline demographic or clinical characteristics were identified between groups.

Table 1: Demographics and Baseline Characteristics							
	TNX-102 SL (N=248)	Placebo (N=255)	Total (N=503)				
Females, %	93.5%	96.9%	95.2%				
White, %	89.5%	84.7%	87.1%				
Not Hispanic or Latino, %	82.7%	83.5%	83.1%				
Married, %	54.4%	54.5%	54.5%				
Avg. age, years	50.0	49.3	49.6				
BMI (kg/m²)	32.4	31.6	32.0				
Unable to work due to FM symptoms, %	6.5%	5.9%	6.2%				
Education, some college or higher, %	82.7%	83.1%	82.9%				
Avg. duration of disease, years	9.2	9.0	9.1				

Topline Results of the RELIEF Study

As seen in Figure 2, the RELIEF study <u>achieved statistical significance</u> on the pre-specified primary efficacy endpoint: change from baseline in weekly average of daily diary pain severity numerical rating scale (NRS) scores for TNX-102 SL 5.6 mg (LS mean [SE]: -1.9 [0.12] units) versus placebo (-1.5 [0.12]



Figures 6 & 7: MCFB in PROMIS Sleep Disturbance and **PROMIS Fatigue**





Table 3: Treatment-Emergent Adverse Events in ≥3% of **Subjects Assigned to TNX**

	TNX-102 SL (N=248)		Placebo (N=255)		Total (N=503)	
Systemic Adverse Events	N	%	N	%	N	%
Sedation	9	3.6	1	0.4	10	2.0
Fatigue	9	3.6	4	1.6	13	2.6
Dry Mouth	8	3.2	7	2.7	15	3.0
Administration Site Reactions	Ν	%	Ν	%	Ν	%
Hypoaesthesia oral	43	17.3	1	0.4	44	8.7
Paraesthesia oral	14	5.6	1	0.4	15	3.0
Product taste abnormal	11	4.4	1	0.4	12	2.4
Glossodynia	9	3.6	2	0.8	11	2.2

DISCUSSION & CONCLUSIONS

- Bedtime TNX at the 5.6 mg dose significantly reduced daily pain (p=0.010) and was associated with a higher rate of \geq 30% pain responders (p=0.006).
- TNX demonstrated robustly improved daily sleep quality (Fig. 8), consistent with the proposed mechanism that TNX targets



Presented at The 5th International Congress on Controversies in Fibromyalgia, March 30-31, 2023

